Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A single- and multiple-dose, open-label pharmacokinetic study in Chinese patients

Li Zhou, Fan‐Yi Meng, Ophelia Yin, Jianxiang Wang, Ying Wang, Yongqiang Wei, Pei Hu, Zhixiang ShenClinical 2009 · DOI

BibTeX
@inproceedings{zhou2009nilotinib,
  author = {Li Zhou and Fan‐Yi Meng and Ophelia Yin and Jianxiang Wang and Ying Wang and Yongqiang Wei and Pei Hu and Zhixiang Shen},
  title = {{Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A single- and multiple-dose, open-label pharmacokinetic study in Chinese patients}},
  booktitle = {Clinical},
  year = {2009},
  doi = {10.1016/j.clinthera.2009.07.016},
}

Loading related content...

Figure